vs
ALPHA PRO TECH LTD（APT）与Enovis CORP（ENOV）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是ALPHA PRO TECH LTD的39.6倍（$548.9M vs $13.9M）。ALPHA PRO TECH LTD净利率更高（5.0% vs -104.1%，领先109.1%）。ALPHA PRO TECH LTD同比增速更快（0.3% vs -2.2%）。Enovis CORP自由现金流更多（$29.1M vs $51.0K）。过去两年Enovis CORP的营收复合增速更高（9.8% vs 1.4%）
Alpha Pro Tech Ltd是一家研发、生产和销售一次性防护服饰、口罩等个人防护用品及耐候屏障等建筑供应产品的企业，核心市场位于北美，主要服务医疗、工业、建筑领域的客户。
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
APT vs ENOV — 直观对比
营收规模更大
ENOV
是对方的39.6倍
$13.9M
营收增速更快
APT
高出2.5%
-2.2%
净利率更高
APT
高出109.1%
-104.1%
自由现金流更多
ENOV
多$29.0M
$51.0K
两年增速更快
ENOV
近两年复合增速
1.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $13.9M | $548.9M |
| 净利润 | $698.0K | $-571.1M |
| 毛利率 | 37.1% | 59.9% |
| 营业利润率 | 6.9% | -101.7% |
| 净利率 | 5.0% | -104.1% |
| 营收同比 | 0.3% | -2.2% |
| 净利润同比 | -17.6% | 18.8% |
| 每股收益（稀释后） | $0.06 | $-9.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APTENOV
| Q4 25 | $13.9M | $548.9M | ||
| Q3 25 | $14.8M | $564.5M | ||
| Q2 25 | $16.7M | $558.8M | ||
| Q1 25 | $13.8M | — | ||
| Q4 24 | $13.8M | $561.0M | ||
| Q3 24 | $14.3M | $505.2M | ||
| Q2 24 | $16.3M | $525.2M | ||
| Q1 24 | $13.5M | $516.3M |
净利润APTENOV
| Q4 25 | $698.0K | $-571.1M | ||
| Q3 25 | $976.0K | $-36.7M | ||
| Q2 25 | $1.2M | $-56.0M | ||
| Q1 25 | $613.0K | — | ||
| Q4 24 | $847.0K | $-703.2M | ||
| Q3 24 | $862.0K | $-31.5M | ||
| Q2 24 | $1.6M | $-18.6M | ||
| Q1 24 | $576.0K | $-72.0M |
毛利率APTENOV
| Q4 25 | 37.1% | 59.9% | ||
| Q3 25 | 39.7% | 59.3% | ||
| Q2 25 | 36.8% | 59.5% | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 37.6% | 54.8% | ||
| Q3 24 | 38.5% | 56.7% | ||
| Q2 24 | 42.0% | 55.0% | ||
| Q1 24 | 40.2% | 57.7% |
营业利润率APTENOV
| Q4 25 | 6.9% | -101.7% | ||
| Q3 25 | 7.4% | -3.0% | ||
| Q2 25 | 8.0% | -8.4% | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 4.9% | -118.5% | ||
| Q3 24 | 5.2% | -6.3% | ||
| Q2 24 | 10.5% | -8.4% | ||
| Q1 24 | 2.4% | -6.8% |
净利率APTENOV
| Q4 25 | 5.0% | -104.1% | ||
| Q3 25 | 6.6% | -6.5% | ||
| Q2 25 | 7.5% | -10.0% | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 6.1% | -125.4% | ||
| Q3 24 | 6.0% | -6.2% | ||
| Q2 24 | 10.1% | -3.5% | ||
| Q1 24 | 4.3% | -13.9% |
每股收益（稀释后）APTENOV
| Q4 25 | $0.06 | $-9.99 | ||
| Q3 25 | $0.09 | $-0.64 | ||
| Q2 25 | $0.12 | $-0.98 | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.07 | $-12.69 | ||
| Q3 24 | $0.08 | $-0.58 | ||
| Q2 24 | $0.15 | $-0.34 | ||
| Q1 24 | $0.05 | $-1.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.0M | $33.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $62.5M | $2.0B |
| 总资产 | $74.1M | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.67× |
8季度趋势，按日历期对齐
现金及短期投资APTENOV
| Q4 25 | $17.0M | $33.6M | ||
| Q3 25 | $17.7M | $44.1M | ||
| Q2 25 | $14.5M | $38.5M | ||
| Q1 25 | $13.4M | — | ||
| Q4 24 | $18.6M | $48.2M | ||
| Q3 24 | $18.4M | $35.4M | ||
| Q2 24 | $16.2M | $35.0M | ||
| Q1 24 | $18.5M | $66.3M |
总债务APTENOV
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B |
股东权益APTENOV
| Q4 25 | $62.5M | $2.0B | ||
| Q3 25 | $62.5M | $2.6B | ||
| Q2 25 | $62.2M | $2.6B | ||
| Q1 25 | $61.7M | — | ||
| Q4 24 | $62.2M | $2.6B | ||
| Q3 24 | $62.1M | $3.3B | ||
| Q2 24 | $62.0M | $3.3B | ||
| Q1 24 | $61.6M | $3.3B |
总资产APTENOV
| Q4 25 | $74.1M | $4.4B | ||
| Q3 25 | $73.9M | $5.0B | ||
| Q2 25 | $73.2M | $4.9B | ||
| Q1 25 | $72.2M | — | ||
| Q4 24 | $73.7M | $4.7B | ||
| Q3 24 | $73.3M | $5.6B | ||
| Q2 24 | $72.7M | $5.4B | ||
| Q1 24 | $72.7M | $5.5B |
负债/权益比APTENOV
| Q4 25 | — | 0.67× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $318.0K | $82.6M |
| 自由现金流经营现金流 - 资本支出 | $51.0K | $29.1M |
| 自由现金流率自由现金流/营收 | 0.4% | 5.3% |
| 资本支出强度资本支出/营收 | 1.9% | 9.7% |
| 现金转化率经营现金流/净利润 | 0.46× | — |
| 过去12个月自由现金流最近4个季度 | $1.7M | $22.8M |
8季度趋势，按日历期对齐
经营现金流APTENOV
| Q4 25 | $318.0K | $82.6M | ||
| Q3 25 | $3.9M | $47.8M | ||
| Q2 25 | $2.1M | $-1.6M | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $2.4M | $88.3M | ||
| Q3 24 | $5.3M | $53.6M | ||
| Q2 24 | $-873.0K | $7.8M | ||
| Q1 24 | $-1.2M | $-36.2M |
自由现金流APTENOV
| Q4 25 | $51.0K | $29.1M | ||
| Q3 25 | $3.8M | $3.4M | ||
| Q2 25 | $1.9M | $-44.9M | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | $970.0K | $35.1M | ||
| Q3 24 | $3.2M | $2.4M | ||
| Q2 24 | $-1.0M | $-31.6M | ||
| Q1 24 | $-1.3M | $-73.1M |
自由现金流率APTENOV
| Q4 25 | 0.4% | 5.3% | ||
| Q3 25 | 25.9% | 0.6% | ||
| Q2 25 | 11.7% | -8.0% | ||
| Q1 25 | -29.6% | — | ||
| Q4 24 | 7.0% | 6.3% | ||
| Q3 24 | 22.3% | 0.5% | ||
| Q2 24 | -6.2% | -6.0% | ||
| Q1 24 | -9.3% | -14.2% |
资本支出强度APTENOV
| Q4 25 | 1.9% | 9.7% | ||
| Q3 25 | 0.7% | 7.9% | ||
| Q2 25 | 0.8% | 7.7% | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 10.4% | 9.5% | ||
| Q3 24 | 15.1% | 10.1% | ||
| Q2 24 | 0.8% | 7.5% | ||
| Q1 24 | 0.6% | 7.2% |
现金转化率APTENOV
| Q4 25 | 0.46× | — | ||
| Q3 25 | 4.02× | — | ||
| Q2 25 | 1.68× | — | ||
| Q1 25 | -6.46× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 6.18× | — | ||
| Q2 24 | -0.53× | — | ||
| Q1 24 | -2.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APT
暂无分部数据
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
